Evotec's Biologics Division Secures Key U.S. Government Contract

Evotec's biologics unit secures a major U.S. government contract for filovirus antibody production, validating its growth strategy amid corporate restructuring.

Amidst a broader corporate restructuring, Evotec SE has received a timely validation of its strategic direction. Its biologics subsidiary, Just – Evotec Biologics, has been awarded a new contract by a U.S. government consortium, providing tangible evidence of the segment's growing importance to the group.

A Strategic Government Award for Filovirus Treatments

The Biomedical Advanced Research and Development Authority (BARDA), part of the BioMaP consortium, has selected Just – Evotec Biologics for a project aimed at optimizing the manufacturing process for a monoclonal antibody cocktail. This treatment targets filoviruses, specifically the Ebola and Sudan viruses. The assignment carries significant weight, as no approved therapy currently exists for the Sudan virus.

Valued at up to $10 million if all options are exercised, the multi-year program includes a base period followed by two potential extension phases. The antibodies in question were originally derived from survivors of the 2014 Ebola outbreak. In its role as a Contract Development and Manufacturing Organization (CDMO) partner—not the license holder—Just – Evotec Biologics will focus on developing scalable and cost-efficient production methods for these therapeutics.

Biologics: A Consistent Engine for Growth

This latest contract aligns with the subsidiary's strong performance trajectory. The biologics unit reported revenue of €259 million for the last fiscal year, representing a substantial 40 percent increase. The BARDA award is seen as a direct endorsement of the platform strategy employed by the division.

On a group level, Evotec is currently implementing its "Horizon" program, launched in early March, which marks the company's next phase of transformation. The new operational model is structured around three core pillars: Operations, Science, and Commercial Execution. Within this framework, the biologics business is regarded as one of the most stable drivers of future growth.

Financial Performance and Market Sentiment

Despite these operational advancements, Evotec's shares continue to face considerable market pressure. Recently trading at €4.17, the stock price sits approximately 31 percent below its 200-day moving average. This valuation largely reflects the company's cautious outlook for 2026, which forecasts revenue between €700 million and €780 million, alongside an adjusted EBITDA guidance of just €0 to €40 million.

Investor attention is now turning to the upcoming release of Evotec's final results for the fourth quarter and full year 2025, scheduled for April 8, 2026. These figures will be crucial in determining whether external contracts, such as the recent BARDA deal, can solidify the biologics division's promising growth narrative or if broader corporate challenges will continue to overshadow positive developments.